SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Posted by Nicole Kennedy on Jan 23rd, 2025

SCYNEXIS, Inc. (NASDAQ:SCYX – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.49 and traded as low as $1.11. SCYNEXIS shares last traded at $1.12, with a volume of 112,390 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of SCYNEXIS from a “sell” rating to a “hold” rating in a research report on Friday, November 8th.

Check Out Our Latest Stock Report on SCYNEXIS

SCYNEXIS Stock Performance

The company has a 50-day moving average of $1.19 and a 200-day moving average of $1.49. The stock has a market cap of $40.23 million, a price-to-earnings ratio of -1.43 and a beta of 1.53.

SCYNEXIS (NASDAQ:SCYX – Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.14. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The business had revenue of $0.66 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in SCYNEXIS stock. XTX Topco Ltd purchased a new position in shares of SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 17,111 shares of the company’s stock, valued at approximately $25,000. Hedge funds and other institutional investors own 54.37% of the company’s stock.

SCYNEXIS Company Profile

(Get Free Report)

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.